2015•UCL Discovery (University College London)Requires access

Raps (rivaroxaban in antiphospholipid syndrome): a prospective randomised controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE

Hannah Cohen, Benjamin Hunt, M Efythymiou, Deepa J. Arachchillage, M. Ruiz, Simon Clawson, Nicola Muirhead, Yvonne Sylvestre, Stephen Machin, María Laura Bertolaccini, Caroline J Doré, IJ Mackie, David Isenberg, Munther A. Khamashta

Open publisher page 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Rivaroxaban, Antiphospholipid syndrome, Medicine, Warfarin, Clinical trial, Internal medicine, Thrombosis, Atrial fibrillation